Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $4.44 down -3.69% from its previous closing price of $4.61. In other words, the price has decreased by -$3.69 from its previous closing price. On the day, 0.94 million shares were traded. ABUS stock price reached its highest trading level at $4.6 during the session, while it also had its lowest trading level at $4.35.
Ratios:
For a deeper understanding of Arbutus Biopharma Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.53 and its Current Ratio is at 20.53. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 21 ’25 when McElhaugh Michael J. bought 246,886 shares for $3.26 per share.
McElhaugh Michael J. bought 53,114 shares of ABUS for $170,098 on Apr 15 ’25. On Mar 31 ’25, another insider, Sofia Michael J., who serves as the Officer of the company, bought 250,000 shares for $3.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 851142208 and an Enterprise Value of 758053184. For the stock, the TTM Price-to-Sale (P/S) ratio is 55.20 while its Price-to-Book (P/B) ratio in mrq is 10.25. Its current Enterprise Value per Revenue stands at 49.173 whereas that against EBITDA is -17.53.
Stock Price History:
The Beta on a monthly basis for ABUS is 0.65, which has changed by 0.22933328 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $5.10, while it has fallen to a 52-week low of $2.70. The 50-Day Moving Average of the stock is 1.42%, while the 200-Day Moving Average is calculated to be 23.62%.
Shares Statistics:
For the past three months, ABUS has traded an average of 1.13M shares per day and 953680 over the past ten days. A total of 191.64M shares are outstanding, with a floating share count of 149.23M. Insiders hold about 22.15% of the company’s shares, while institutions hold 61.82% stake in the company. Shares short for ABUS as of 1760486400 were 9863869 with a Short Ratio of 8.76, compared to 1757894400 on 11160517. Therefore, it implies a Short% of Shares Outstanding of 9863869 and a Short% of Float of 7.31.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Arbutus Biopharma Corp (ABUS).The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.03 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.22 and -$0.29 for the fiscal current year, implying an average EPS of -$0.25. EPS for the following year is -$0.25, with 3.0 analysts recommending between -$0.23 and -$0.29.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for ABUS’s current fiscal year. The highest revenue estimate was $22.26M, while the lowest revenue estimate was $17.18M, resulting in an average revenue estimate of $19.85M. In the same quarter a year ago, actual revenue was $8.8M
